Our Science

Targeting Adenosine Signaling Across Disease Areas

Cyncado is advancing a platform of selective adenosine receptor antagonists, TT-4 (A2B) and TT-10 (A2A), across oncology, neurology, and hematologic disease.

Oncology

Mesothelioma
Solid Tumors

Neurology

Parkinson's Disease

Hematologic

Sickle Cell Disease

Explore Our Pipeline

See where TT-4 and the broader Cyncado portfolio sit in clinical development.

View PipelineMesothelioma Awareness